Clinical trials have shown that oral antiretrovirals (ARVs) containing tenofovir/emtricitabine used by HIV-negative individuals to prevent HIV acquisition, called oral pre-exposure prophylaxis (PrEP), are safe and effective in several populations. Prior modeling work has demonstrated that oral PrEP is most cost effective when targeted to populations at very high risk of infection, with risk dependent on a combination of individual behavior and epidemic contexts. This brief describes a study Project SOAR is conducting to assist Uganda and Swaziland in making critical decisions about oral PrEP introduction and scale up by modeling the expected cost effectiveness and impact of oral PrEP within each country’s larger portfolio of HIV-prevention interventions.
Project SOAR. 2018. "Modeling the expected cost-effectiveness and impact of oral pre-exposure prophylaxis in Uganda and Swaziland," Project SOAR Activity Brief. Washington, DC: Population Council.
Supporting Operational AIDS Research (Project SOAR)